AKTX — Akari Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Akari Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 9.36 | 13.2 | 3.85 | 2.6 | 5.2 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 11.6 | 13.8 | 4.34 | 2.95 | 5.46 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Total Assets | 11.6 | 13.8 | 4.36 | 50.6 | 47.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.09 | 12 | 4.58 | 19.9 | 12.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.09 | 12 | 4.58 | 28.3 | 19.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 5.55 | 1.79 | -0.229 | 22.2 | 28.3 |
| Total Liabilities & Shareholders' Equity | 11.6 | 13.8 | 4.36 | 50.6 | 47.9 |
| Total Common Shares Outstanding |